Tru Independence LLC Acquires 85 Shares of Johnson & Johnson (NYSE:JNJ)
Tru Independence LLC Acquires 85 Shares of Johnson & Johnson (NYSE:JNJ)
tru Independence LLC raised its holdings in Johnson & Johnson (NYSE:JNJ – Get Rating) by 0.3% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 27,816 shares of the company's stock after buying an additional 85 shares during the quarter. tru Independence LLC's holdings in Johnson & Johnson were worth $4,543,000 at the end of the most recent quarter.
据特鲁独立有限责任公司在最近提交给美国证券交易委员会的13F文件中称，该公司在第三季度将其在强生(纽约证券交易所代码：JNJ-GET评级)的持股增加了0.3%。该基金持有27,816股该公司股票，该基金在本季度又购买了85股。截至最近一个季度末，Tru独立有限责任公司持有的强生股份价值4,543,000美元。
A number of other large investors have also recently made changes to their positions in JNJ. DORCHESTER WEALTH MANAGEMENT Co boosted its position in shares of Johnson & Johnson by 8.6% during the first quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 67,618 shares of the company's stock valued at $14,975,000 after purchasing an additional 5,327 shares in the last quarter. Cantor Fitzgerald Investment Advisor L.P boosted its position in shares of Johnson & Johnson by 88.9% during the first quarter. Cantor Fitzgerald Investment Advisor L.P now owns 175,194 shares of the company's stock valued at $31,049,000 after purchasing an additional 82,429 shares in the last quarter. AMI Investment Management Inc. boosted its position in shares of Johnson & Johnson by 8.8% during the first quarter. AMI Investment Management Inc. now owns 18,305 shares of the company's stock valued at $3,244,000 after purchasing an additional 1,475 shares in the last quarter. Equitable Holdings Inc. boosted its position in shares of Johnson & Johnson by 4.9% during the first quarter. Equitable Holdings Inc. now owns 45,673 shares of the company's stock valued at $8,095,000 after purchasing an additional 2,119 shares in the last quarter. Finally, USS Investment Management Ltd boosted its position in shares of Johnson & Johnson by 2.4% during the first quarter. USS Investment Management Ltd now owns 860,371 shares of the company's stock valued at $152,488,000 after purchasing an additional 20,528 shares in the last quarter. 67.94% of the stock is currently owned by institutional investors.
其他一些大型投资者最近也调整了他们在JNJ的仓位。今年第一季度，多切斯特财富管理公司将其持有的强生股票的仓位提高了8.6%。多切斯特财富管理公司目前拥有67,618股该公司股票，价值14,975,000美元，此前该公司在上个季度又购买了5,327股。第一季度，康托菲茨杰拉德投资顾问公司将其持有的强生股票仓位提高了88.9%。Cantor Fitzgerald Investment Advisor L.P在上个季度额外购买了82,429股后，现在拥有175,194股该公司股票，价值31,049,000美元。今年第一季度，阿美投资管理公司将其持有的强生股票头寸提高了8.8%。阿美投资管理公司目前持有18,305股该公司股票，价值3,244,000美元，该公司在上个季度又购买了1,475股。今年第一季度，公平控股公司将其持有的强生股票头寸提高了4.9%。Equity Holdings Inc.在上个季度又购买了2,119股后，现在持有45,673股该公司股票，价值8,095,000美元。最后，USS投资管理有限公司在第一季度将其持有的强生股票的头寸提高了2.4%。USS投资管理有限公司在上个季度额外购买了20,528股后，现在拥有860,371股该公司的股票，价值152,488,000美元。67.94%的股票目前由机构投资者持有。
Insider Activity at Johnson & Johnson
强生的内幕活动
In related news, EVP Jennifer L. Taubert sold 76,923 shares of the company's stock in a transaction on Tuesday, November 22nd. The stock was sold at an average price of $176.78, for a total transaction of $13,598,447.94. Following the completion of the sale, the executive vice president now owns 126,456 shares in the company, valued at $22,354,891.68. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Johnson & Johnson news, CFO Joseph J. Wolk sold 14,781 shares of the business's stock in a transaction dated Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total transaction of $2,654,667.60. Following the completion of the sale, the chief financial officer now owns 35,812 shares of the company's stock, valued at $6,431,835.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Jennifer L. Taubert sold 76,923 shares of the business's stock in a transaction dated Tuesday, November 22nd. The shares were sold at an average price of $176.78, for a total value of $13,598,447.94. Following the sale, the executive vice president now directly owns 126,456 shares of the company's stock, valued at approximately $22,354,891.68. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 233,611 shares of company stock worth $40,960,735. 0.35% of the stock is owned by insiders.
在相关新闻中，执行副总裁詹妮弗·L·陶伯特在11月22日(星期二)的一笔交易中出售了76,923股该公司股票。股票以176.78美元的平均价格出售，总成交金额为13,598,447.94美元。出售完成后，执行副总裁总裁现在拥有该公司126,456股股份，价值22,354,891.68美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，该文件可以通过此超链接。在强生的另一则消息中，首席财务官约瑟夫·沃尔克在12月13日(星期二)的交易中出售了14,781股该公司的股票。该股以179.60美元的平均价格出售，总成交金额为2654,667.60美元。出售完成后，首席财务官现在拥有该公司35,812股股票，价值6,431,835.20美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，该文件可通过美国证券交易委员会网站。此外，执行副总裁詹妮弗·L·陶伯特在11月22日星期二的交易中出售了76,923股该公司股票。这些股票的平均价格为176.78美元，总价值为13,598,447.94美元。出售后，执行副总裁总裁现在直接持有该公司126,456股股票，价值约22,354,891.68美元。关于这次销售的披露可以找到这里。在过去的90天里，内部人士卖出了233,611股公司股票，价值40,960,735美元。该公司0.35%的股份由内部人士持有。
Johnson & Johnson Stock Down 0.4 %
强生股价下跌0.4%
Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its quarterly earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share for the quarter, topping the consensus estimate of $2.22 by $0.13. The firm had revenue of $23.71 billion during the quarter, compared to analysts' expectations of $23.90 billion. Johnson & Johnson had a return on equity of 35.94% and a net margin of 18.90%. The company's revenue was down 4.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.13 earnings per share. Equities analysts forecast that Johnson & Johnson will post 10.52 earnings per share for the current fiscal year.
强生(纽约证券交易所代码：JNJ-GET Rating)最近一次公布季度收益报告是在1月24日，星期二。该公司公布本季度每股收益为2.35美元，比普遍预期的2.22美元高出0.13美元。该公司本季度营收为237.1亿美元，高于分析师预期的239亿美元。强生的股本回报率为35.94%，净利润率为18.90%。该公司的收入同比下降了4.4%。去年同一季度，该业务每股收益为2.13美元。股票分析师预测，强生本财年每股收益将达到10.52欧元。
Johnson & Johnson Dividend Announcement
强生分红公告
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st will be given a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a yield of 2.69%. The ex-dividend date is Friday, February 17th. Johnson & Johnson's dividend payout ratio (DPR) is presently 67.06%.
该公司最近还披露了季度股息，将于3月7日(星期二)支付。2月21日(星期二)登记在册的投资者将获得每股1.13美元的股息。这意味着年化股息为4.52美元，收益率为2.69%。除息日期为2月17日星期五。强生目前的股息支付率为67.06%。
Analyst Ratings Changes
分析师评级发生变化
Several equities research analysts recently weighed in on the company. Credit Suisse Group assumed coverage on Johnson & Johnson in a research report on Thursday, November 17th. They set a "neutral" rating and a $170.00 price target on the stock. Sanford C. Bernstein dropped their target price on Johnson & Johnson from $194.00 to $190.00 in a report on Wednesday, October 19th. Morgan Stanley boosted their target price on Johnson & Johnson from $176.00 to $180.00 and gave the stock an "equal weight" rating in a report on Wednesday. SVB Leerink dropped their target price on Johnson & Johnson from $194.00 to $186.00 and set an "outperform" rating on the stock in a report on Friday, January 20th. Finally, Barclays started coverage on Johnson & Johnson in a report on Monday, October 17th. They issued an "equal weight" rating and a $175.00 target price on the stock. Seven equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Johnson & Johnson has a consensus rating of "Moderate Buy" and an average target price of $182.75.
几位股票研究分析师最近对该公司进行了分析。瑞士信贷集团在11月17日星期四的一份研究报告中对强生进行了报道。他们为该股设定了“中性”评级和170.00美元的目标价。桑福德·伯恩斯坦在10月19日星期三的一份报告中将强生的目标价从194.00美元下调至190.00美元。摩根士丹利在周三的一份报告中将强生的目标价从176.00美元上调至180.00美元，并给予该股“同等权重”的评级。SVB Leerink在1月20日(星期五)的一份报告中将强生的目标价从194.00美元下调至186.00美元，并对该股设定了“跑赢大盘”的评级。最后，巴克莱在10月17日星期一的一份报告中开始了对强生的报道。他们对该股给予了“同等权重”的评级和175.00美元的目标价。7名股票研究分析师对该股的评级为持有，5名分析师给予了买入评级，一名分析师给予了该公司强烈的买入评级。根据MarketBeat.com的数据，强生的共识评级为“适度买入”，平均目标价为182.75美元。
About Johnson & Johnson
关于强生
(Get Rating)
(获取评级)
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets.
强生是一家控股公司，从事医疗保健领域产品的研发、制造和销售。它通过以下细分市场运作：消费者健康、制药和医疗设备。消费者健康部分包括用于婴儿护理、口腔护理、美容、非处方药、妇女健康和伤口护理市场的产品。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- MarketBeat Week in Review – 1/23- 1/27
- Why Lucid Spiked Nearly 100% In One Day
- Ride These Railroad Stocks for Growth and Income
- ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
- KLA Corporation: Strength In A Troubled Semi-Market
- 免费获取斯托克新闻网关于强生(JNJ)的研究报告
- 市场回顾周-1/23-1/27
- 为什么Lucid在一天内飙升了近100%
- 利用这些铁路股票实现增长和收入
- ASML预计今年芯片需求回升，提振销售观点
- KLA公司：在动荡不安的半市场中站稳脚跟
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
想看看其他对冲基金持有JNJ的是什么吗？访问HoldingsChannel.com获取强生(纽约证券交易所代码：JNJ-GET Rating)的最新13F文件和内幕交易信息。
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
接受《强生日报》的新闻和评级-在下面输入您的电子邮件地址，即可通过MarketBeat.com的免费每日电子邮件时事通讯接收对强生及相关公司的最新新闻和分析师评级的每日摘要。